15.11.2021 • NewsJohnson & Johnson

Johnson & Johnson to Split Consumer from Pharma

Another US healthcare business is being split into separate parts or separated from other parts of a diverse group. First General Electric, with its health segment, went on the chopping block. This time the axe will hit the venerable Johnson & Johnson, founded in 1886 a maker of surgical dressings.

New Jersey-based J&J announced on Nov. 12 that it plans to carve out its consumer products activities (bandages, beauty products and headache tablets) into a separate publicly traded entity. The remaining businesses will continue to produce and sell pharmaceuticals and medical devices, which represent the more profitable end.

No new name has been revealed for the consumer company, nor did J&J say whether it might be up for sale.

Following a comprehensive review, Johnson & Johnson said its board and management team believe the planned spilt is “the best way to accelerate its efforts to serve patients, consumers and healthcare professionals, create opportunities its global teams and drive profitable growth.”

The pharmaceutical and medical devices division of the largest US healthcare company – and by some calculations the world’s largest – expects to report $77 billion in sales revenue this year, with the consumer health business bringing in $15 billion.

J&J plans to complete the breakup within two years as it hones its focus on each of the two very different types of businesses. “We must continually be evolving our business to provide value today, tomorrow and in the decades ahead,” CEO Alex Gorsky said.  With the split, he said the pharma and medical device arm will continue to concentrate on “bringing new solutions to market for patients and healthcare systems, while creating sustainable value for shareholders.”

Separately, the two independent business will be able to “more effectively allocate resources to deliver for patients and consumers, drive growth and unlock significant value,” said Joachin Duato, who currently heads the pharmaceutical division and will succeed Gorsky as CEO at the beginning of next year. Both would remain “mission driven companies with exceptional brands.”

The still integrated healthcare group has faced challenges to face on multiple fronts in recent years. The consumer business has been hit with thousands of lawsuits charging that its talc-based baby powder caused their cancer, and its pharma side has been caught up in the wide-sweeping US opioid crisis. While J&J’s Covid-19 vaccine has not lived up to its efficacy promise, and, moreover, has faced production setbacks, this business accounts for only about $2.5 billion in annual sales.

Last month, Johnson & Johnson took the baby powder business into US Chapter 11 bankruptcy proceedings, under a holding company called LTL.  Lawyers representing more than 30,000 women who have claim that the powder caused their cancer, have vowed to fight the company’s action.

J&J did see a ray of light last week, however. After the group agreed last July to pay $5 billion over nine years to settle lawsuits in the ongoing US opioid trials, the supreme court of the state of Oklahoma threw out a 2019 ruling that would have required the manufacturer to pay the state $465 million for its role in the epidemic.

Author: Dede Williams, Freelance Journalist

Another healthcare business is being split up or carved out, and this time the...
Another healthcare business is being split up or carved out, and this time the axe will hit Johnson Johnson. The venerable company, founded in 1886, has said it will separate its consumer productions activities (bandages, beauty products and headache tablets ) from its more profitable) pharmaceuticals (Janssen) and medical devices businesses. (c) Johnson Johnson

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
08.11.2024 • News

Future Prospects in Green Chemistry

The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.

Photo
24.01.2025 • News

And the Winners are: Cynio, EnaDyne and Green Li-ion

The CHEManager Innovation Pitch, the start-up promotion initiative of CHEManager and CHEManager International, has given more than 100 start-ups from over 15 countries the opportunity to present their innovative ideas, products and technologies to a broad target group since its launch in 2019.